Results 11 to 20 of about 609 (139)

Multimodal Imaging in Pachychoroid Neovasculopathy: A Case Report [PDF]

Türk Oftalmoloji Dergisi, 2018
Pachychoroid neovasculopathy (PNV) is a form of type 1 neovascularization characterized by dilated choroidal vessels in areas of increased choroidal thickness. In this article, we describe a patient diagnosed with PNV.
Özlem Biçer, Figen Batıoğlu, Sibel Demirel, Emin Özmert   +3 more
doaj   +7 more sources

Short-Wavelength and Infrared Autofluorescence Imaging in Pachychoroid Neovasculopathy [PDF]

Vision
Purpose: The purpose of this paper is to investigate the relationship between short-wavelength autofluorescence (SWAF) and infrared autofluorescence (IRAF) patterns in pachychoroid neovasculopathy (PNV) with serous retinal detachment (SRD). Methods: This
Norihiko Nakagawa, Takuya Shunto, Issei Nishiyama, Kohei Maruyama, Miki Sawa   +4 more
doaj   +5 more sources

Choroidal caverns in pachychoroid neovasculopathy

Acta Biomedica Scientifica, 2021
Background. Choroid plays an important role in the pathogenesis of retinal pathology. Choroidal cavern, a recently identifi ed fi nding of optical coherent tomography (OCT), has been described in some degenerative and atrophic forms of retinal pathology.
E. K. Pedanova
doaj   +4 more sources

Pachychoroid neovasculopathy in extramacular choroidal neovascularization

Clinical Ophthalmology, 2016
Mrinali Patel Gupta, Irene Rusu, Carly Seidman, Anton Orlin, Donald J D’Amico, Szilard Kiss Department of Ophthalmology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA Purpose: To review a series of extramacular ...
Gupta MP, Rusu I, Seidman C, Orlin A, D'Amico DJ, Kiss S   +5 more
doaj   +6 more sources

Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy [PDF]

BMC Ophthalmology, 2021
Background To investigate the diagnostic value of choroidal thickness in the definition of pachychoroid neovasculopathy (PNV), especially in eyes treated with anti-vascular endothelial growth factor (VEGF) therapy.
Benedikt Schworm, Nikolaus Luft, Leonie F. Keidel, Thomas C. Kreutzer, Tina R. Herold, Siegfried G. Priglinger, Jakob Siedlecki   +6 more
doaj   +3 more sources

A Comparative Study of Short-Term Vascular and Stromal Alterations of the Choroid Following Half-Fluence Photodynamic Therapy in Pachychoroid Neovasculopathy and Chronic Central Serous Chorioretinopathy [PDF]

Life, 2022
Background: Central serous chorioretinopathy (CSCR) and pachychoroid neovasculopathy (PNV) are among the pachychoroid spectrum diseases (PSDs). Half-fluence photodynamic therapy (hf-PDT) is one of the effective treatment methods for both diseases.
Özge Yanık, Sibel Demirel, Figen Batıoğlu, Emin Özmert   +3 more
doaj   +3 more sources

Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. [PDF]

PLoS ONE, 2021
This multicenter retrospective study was conducted to evaluate the 1-year treatment outcome of photodynamic therapy (PDT) combined with anti-vascular endothelial growth factor (VEGF) therapy for pachychoroid neovasculopathy (PNV).
Akiko Miki, Sentaro Kusuhara, Tsuyoshi Otsuji, Yu Kawashima, Katsuaki Miki, Hisanori Imai, Makoto Nakamura, Akitaka Tsujikawa   +7 more
doaj   +4 more sources

Choroidal caverns in pachychoroid neovasculopathy

Indian Journal of Ophthalmology, 2020
Apoorva Ayachit, Shrinivas Joshi, S V Kathyayini, Guruprasad Ayachit   +3 more
doaj   +4 more sources

Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy [PDF]

Scientific Reports
To evaluate the short-term treatment outcomes of 80% dose photodynamic therapy (PDT) combined with intravitreal aflibercept injection (IVA) for symptomatic pachychoroid neovasculopathy (PNV) in a working-age population.
Norihiko Nakagawa, Kohei Maruyama, Issei Nishiyama, Miki Sawa   +3 more
doaj   +4 more sources

Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy. [PDF]

Transl Vis Sci Technol, 2023
To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy.Retrospective analysis of 34 eyes treated with intravitreal brolucizumab.
Carosielli M, Carnevali A, Fallico M, Pirozzi E, Chiosi F, Chronopoulos A, Cucciniello P, Affatato M, Rapino G, dell'Omo R, BROCS study group, BROCS (BROlucizumab for the treatment of Central Serous chorioretinopathy) study group†.   +11 more
europepmc   +5 more sources